INTERNATIONAL PATENT: RIGEL PHARMACEUTICALS, INC. FILES APPLICATION FOR "TREATMENT OF CNS TUMORS WITH OLUTASIDENIB AND TEMOZOLOMIDE"

GENEVA, Sept. 17 -- RIGEL PHARMACEUTICALS, INC. (611 Gateway Boulevard, Suite 900South San Francisco, CA 94080) filed a patent application (PCT/US2025/018173) for "TREATMENT OF CNS TUMORS WITH OLUTASIDENIB AND TEMOZOLOMIDE" on Mar 03, 2025. With publication no. WO/2025/188644, the details related to the patent application was published on Sep 11, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): CHAO, Mwe Mwe (c/o Rigel Pharmaceuticals, Inc.611 Gateway Boulevard, Suite 900South San Francisco, CA 94080), TONG, Sandra (c/o Rigel Pharmaceuticals, Inc.611 Gateway Boulevard, Suite 900South San Fran...